Overactivation of the PI3K/AKT/mTOR pathway, due to the loss of the tumor suppressor gene phosphatase and tensin homolog (PTEN), has been observed in more than 40% of type I endometrial cancers. This evidence concerns the gene PTEN and endometrial cancer.